Biotech Company News

Bristol-Myers Squibb to Acquire Celgene

Bristol-Myers bulks up cancer portfolio with $74 billion Celgene deal (Reuters) - Bristol-Myers Squibb Co (BMY.N) said on Thursday it would buy Celgene Corp (CELG.O) for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy space heats up. Bristol-Myers pioneered immunotherapy with its Yervoy and later Opdivo, but has come under pressure as Merck & Co’s (MRK.N) rival treatment Keytruda moved